Prolocor
BioTech/Drugs - N/A, N/A, us
Prolocor Employees
Prolocor Senior Management
Prolocor Details
There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over 2 million suffer from acute coronary syndrome every year. In each case, the doctor and patient must decide whether to use more powerful therapy to prevent thrombosis – increasing the risk of bleeding – or less intensive therapy – reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke, and cardiovascular death. Prolocor's precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events. Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets. We are currently building a website that will tell much more about our amazing science and the mechanism behind our novel and highly predictive diagnostic test. Stay tuned and follow us for updates on the Prolocor website launch.
Prolocor Technologies
Email Providers
Outlook
Load Balancers
Ubuntu
Tag Management
Google Tag Manager
Other
Mobile Friendly